Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction.
Timothy D HenryC Noel Bairey MerzJanet WeiMichel T CorbanOdayme QuesadaSandy JoungChristine L KotynskiJian WangMichelle LewisAnn M SchumacherRonnda L BartelHiroshi TakagiVishal ShahAnna LeeWilliam K SietsemaDouglas W LosordoAmir LermanPublished in: Circulation. Cardiovascular interventions (2022)
In this pilot clinical trial of microvascular angina, patients with ischemia and nonobstructive coronary artery disease receiving intracoronary infusion of CD34+ cell therapy had higher coronary flow reserve, less severe angina, and better quality of life at 6 months. The current study supports a potential therapeutic role for CD34+ cells in patients with microvascular angina. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03508609.
Keyphrases
- coronary artery disease
- cell therapy
- coronary artery
- stem cells
- percutaneous coronary intervention
- cardiovascular events
- coronary artery bypass grafting
- clinical trial
- mesenchymal stem cells
- aortic stenosis
- nk cells
- induced apoptosis
- study protocol
- low dose
- randomized controlled trial
- cell cycle arrest
- early onset
- acute coronary syndrome
- bone marrow
- cardiovascular disease
- signaling pathway
- atrial fibrillation
- aortic valve
- hypertrophic cardiomyopathy